Indeed, epigenetic potentiation of the NY-ESO-1 protein vaccine with montanide-based adjuvant using decitabine, a DNMT inhibitor, has been successful in treating epithelial ovarian cancer (28). This evidence concerns the gene DNMT1 and ovarian carcinoma.